Nutriband (NTRB) AI Stock Analysis

• Market Cap: $84.97M
• Dividend Yield: N/A
• Average Volume (3M): 30.09K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.41
• Revenue Growth: 42.92%
• EPS Growth: -251.69%
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.98
• Shares Outstanding: 12,034,883
• 10 Day Avg. Volume: 24,245
• 30 Day Avg. Volume: 30,095
• PEG Ratio: -0.19
• Price to Book (P/B): 13.68
• Price to Sales (P/S): 41.09
• P/FCF Ratio: -18.63
• Enterprise Value/Market Cap: 0.71
• Enterprise Value/Revenue: 23.25
• Enterprise Value/Gross Profit: 70.13
• Enterprise Value/Ebitda: -6.00
• 1Y Price Target: $15.00
• Price Target Upside: 112.46% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 53 Neutral
• Price Target: $7.50 ▲(6.23% Upside)

Nutriband's overall stock score is driven by a strong corporate event with positive market reception, offset by challenging financial performance and valuation issues. The technical analysis provides mixed signals, suggesting cautious optimism. The potential for shareholder value enhancement through recent corporate actions improves the score despite underlying financial weaknesses.

Positive Factors

Business Model Strength

Nutriband's focus on transdermal drug delivery systems offers a unique value proposition in healthcare, enhancing patient compliance and therapeutic outcomes.

Strategic Collaborations

Partnerships with pharmaceutical companies for co-development and licensing agreements expand market access and support revenue growth.

Shareholder Value Enhancement

Issuing Series A Preferred Stock positions Nutriband favorably in the market, potentially increasing shareholder value and financial stability.

Negative Factors

Profitability Challenges

Ongoing operational losses and negative cash flows indicate difficulty in achieving profitability, impacting long-term business sustainability.

Negative Cash Flow

Reliance on financing to offset cash deficits is unsustainable, posing risks to financial health if operational improvements are not realized.

Volatile Profit Margins

Inconsistent profit margins highlight challenges in cost management, affecting long-term profitability and competitive positioning.

Nutriband Business Overview & Revenue Model

Company Description

Nutriband (NTRB) is a biotechnology company focused on developing innovative transdermal drug delivery systems. Operating primarily in the healthcare sector, Nutriband specializes in creating wearable patches that administer medications and supplements efficiently through the skin. Their core products include the Nutriband patch technology, which aims to enhance patient compliance and improve therapeutic outcomes for various medical applications, such as pain management and chronic conditions.

How the Company Makes Money

Nutriband generates revenue through the commercialization of its transdermal patch products. The company primarily earns money by selling its patches directly to healthcare providers and distributors, as well as through partnerships with pharmaceutical companies for co-development and licensing agreements. Additionally, Nutriband may benefit from royalties on sales of products developed utilizing its technology. Strategic collaborations with industry players enhance its market reach and provide additional financial backing, contributing to the overall revenue model.

Nutriband Financial Statement Overview

Summary

Nutriband faces significant challenges in improving profitability and cash flow. While there is some revenue growth, persistent losses and negative cash flows are critical issues. The balance sheet is stable due to low leverage, but ongoing losses and reliance on external financing could pose risks.

Income Statement

Nutriband has shown modest revenue growth over the years, but profitability remains a challenge with consistently negative EBIT and net income margins. Revenue increased by 2.6% from 2024 to 2025, indicating slow growth. However, the gross profit margin has been volatile, and the net profit margin remains deeply negative, reflecting the company's difficulty in managing costs in relation to revenues.

Balance Sheet

The balance sheet is relatively stable, with a low debt-to-equity ratio indicating conservative leverage. Stockholders' equity remains strong at approximately 86% of total assets. However, the company's return on equity is negative due to ongoing net losses, which could be concerning for long-term sustainability.

Cash Flow

Nutriband's cash flow situation is challenging, with negative operating and free cash flows reflecting ongoing operational losses. The operating cash flow to net income ratio is negative, indicating cash outflows exceed net losses. The company relies heavily on financing cash flows to offset operating cash deficits, which is not sustainable long-term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.58M	2.14M	2.09M	2.08M	1.42M	943.70K
Gross Profit	854.67K	699.30K	862.11K	750.41K	504.31K	361.32K
EBITDA	-10.00M	-10.18M	-5.12M	-4.11M	-5.74M	-2.48M
Net Income	-10.27M	-10.48M	-5.49M	-4.81M	-8.42M	-3.21M
Balance Sheet
Total Assets	10.18M	7.47M	7.52M	9.46M	12.74M	9.93M
Cash, Cash Equivalents and Short-Term Investments	7.00M	4.31M	492.94K	1.99M	4.89M	151.99K
Total Debt	223.06K	186.35K	241.28K	185.81K	134.57K	1.79M
Total Liabilities	1.68M	1.04M	1.08M	883.39K	880.38K	2.82M
Stockholders Equity	8.49M	6.43M	6.44M	8.57M	11.86M	7.11M
Cash Flow
Free Cash Flow	-4.94M	-4.72M	-3.58M	-3.07M	-2.89M	-297.06K
Operating Cash Flow	-4.90M	-4.63M	-3.53M	-2.99M	-2.81M	-297.06K
Investing Cash Flow	-46.96K	-92.04K	-51.76K	-79.30K	-81.59K	66.99K
Financing Cash Flow	5.19M	8.54M	2.09M	160.07K	7.63M	371.87K

Nutriband Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.06
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTRB, the sentiment is Positive. The current price of 7.06 is above the 20-day moving average (MA) of 6.80, above the 50-day MA of 6.97, and above the 200-day MA of 6.53, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 52.59 is Neutral, neither overbought nor oversold. The STOCH value of 52.96 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NTRB.

Nutriband Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NTRB	53 Neutral	$84.97M	―	-98.00%	―	42.92%	-251.69%
AVTX	52 Neutral	$142.05M	-1.15	-26.41%	―	-45.35%	96.80%
CBUS	42 Neutral	$70.53M	-0.12	-381.75%	―	63.66%	36.72%
ANRO	42 Neutral	$106.95M	-1.65	―	―	―	―
SER	40 Neutral	$50.95M	-0.84	-1738.07%	―	34.04%	55.34%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Nutriband Corporate Events

Nutriband Completes Stock Dividend of Preferred Shares

On July 9, 2025, Nutriband‘s Board of Directors approved an amendment to authorize a series of non-voting Series A Convertible Preferred Stock, increasing the authorized shares to 10,000,000. Subsequently, on August 5, 2025, Nutriband completed a stock dividend, issuing 3,008,643 shares of Series A Preferred Stock to its shareholders, with these shares held as restricted stock until eligible for conversion and registration with the SEC.

Nutriband Approves New Series A Preferred Stock

On July 9, 2025, Nutriband Inc.’s Board of Directors approved an amendment to its Articles of Incorporation to authorize a new series of non-voting shares, the Series A Convertible Preferred Stock. This amendment allows for the issuance of 2,788,678 shares of Series A Preferred Stock, which can be converted into common stock following FDA approval of the company’s transdermal products. The company also announced a preferred stock dividend, with one share of Series A Preferred stock issued for every four shares of common stock held, with a record date of July 25, 2025. This move could potentially enhance shareholder value and position the company favorably in the market.